Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 983 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Coronary Syndrome Clear all
Completed Phase 1Phase 2 Interventional Results available

Healthy Heart Habits

NCT04158219
View directory record Official record
Conditions
Acute Coronary Syndrome, Depression
Interventions
Behavioral activation for health and depression (BA-HD)
Behavioral
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants With Acute Coronary Syndrome

NCT02293395
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Acetylsalicylic acid, Rivaroxaban, Clopidogrel, Ticagrelor
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
3,037 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
49
States / cities
Alexander City, Alabama • Banning, California • Sylmar, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Phase 2 Interventional Results available

Effect of Prasugrel on Platelets After One Week in Patients Already Taking Clopidogrel After a Cardiac Event

NCT00356135
View directory record Official record
Conditions
Coronary Arteriosclerosis, Acute Coronary Syndrome
Interventions
prasugrel 10 mg, clopidogrel, prasugrel placebo, prasugrel 60 mg, clopidogrel placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 74 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
9
States / cities
Jacksonville, Florida • Baltimore, Maryland • Worcester, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2010 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Phase 3 Interventional

Angiomax in Patients With HIT/HITTS Type II Undergoing CPB

NCT00079508
View directory record Official record
Conditions
Cardiovascular Disease, Coronary Artery Bypass Surgery
Interventions
Angiomax (bivalirudin)
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 10, 2011 · Synced Oct 5, 2026, 5:50 AM EDT
Not yet recruiting Phase 1 Interventional

Study of Intramyocardial Injection of Ventrix Bio Extracellular Matrix (VentriGel) to Assess the Safety and Feasibility in Pediatric Patients with Hypoplastic Left Heart Syndrome (HLHS)

NCT06461676
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome
Interventions
Ventrix Bio Extracellular Matrix
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 1 Year
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 5, 2026, 5:50 AM EDT
Completed No phase listed Observational

5th Generation cTnT in ED ACS

NCT03590535
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
4th Gen cTnT, 5th Gen cTnT
Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
19 Years and older
Enrollment
1,949 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2022 · Synced Oct 5, 2026, 5:50 AM EDT
Recruiting Phase 3 Interventional

A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections

NCT06056297
View directory record Official record
Conditions
Neutropenia
Interventions
Mavorixafor, Placebo
Drug
Lead sponsor
X4 Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
22
States / cities
Phoenix, Arizona • Irvine, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

Effectiveness of Pacemaker With Closed Loop Stimulation Compared to Pacemakers With and Without Standard Rate Response

NCT00355797
View directory record Official record
Conditions
Bradycardia
Interventions
Closed Loop Stimulation (CLS), Standard Rate Adaptive (R) Technology, Non-rate adaptive (DDD) pacing
Device
Lead sponsor
Biotronik, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
99
States / cities
Albertville, Alabama • Gadsden, Alabama • Jasper, Alabama + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2012 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Children and Adolescents With Marfan Syndrome: 10,000 Healthy Steps and Beyond

NCT03567460
View directory record Official record
Conditions
Marfan Syndrome
Interventions
Exercise
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 19 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Not applicable Interventional

Rapid Acute Coronary Syndrome Exclusion Using High-sensitivity I Troponin

NCT04488913
View directory record Official record
Conditions
Chest Pain, Myocardial Ischemia
Interventions
RACE-IT Pathway, Standard of Care
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
32,609 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Oct 5, 2026, 5:50 AM EDT
Completed No phase listed Observational

Biomarker Study for Heart Failure in Children With Single Ventricle Physiology

NCT00571233
View directory record Official record
Conditions
Tricuspid Atresia, Hypoplastic Left Heart Syndrome, Unbalanced AV Canal
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
1 Month to 6 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 5, 2026, 5:50 AM EDT
Not listed Phase 4 Interventional

Safety and Efficacy of the Novel Selective Nicotinic Receptor Partial Agonist, CHANTIX (Varenicline) in Patients With Acute Coronary Syndrome

NCT01170338
View directory record Official record
Conditions
Smoking, Acute Coronary Syndrome
Interventions
Varenicline 100 mg by mouth twice daily, control
Drug
Lead sponsor
Newark Beth Israel Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2010 · Synced Oct 5, 2026, 5:50 AM EDT
Recruiting Not applicable Interventional

Ventilator Pressure and Optimization of Compliance and Hemodynamics

NCT06512935
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
Interventions
Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Days to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 5, 2026, 5:50 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Race Difference Moxifloxacin-induced QT Prolongation Between Healthy Chinese and Caucasian Volunteers

NCT02119091
View directory record Official record
Conditions
Cardiac Toxicity
Interventions
Moxifloxacin
Drug
Lead sponsor
Haiyan Li
Other
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2014 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Acute Coronary Syndrome KCMC

NCT04563546
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Quality Improvement
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 31, 2025 · Synced Oct 5, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

Effect of Fetal Aortic Valvuloplasty on Outcomes

NCT05386173
View directory record Official record
Conditions
Congenital Heart Disease, Aortic Valve Stenosis, Fetal Cardiac Disorder, Hypoplastic Left Heart Syndrome
Interventions
Fetal aortic balloon dilatation
Procedure
Lead sponsor
Queen Silvia Children's Hospital, Gothenburg, Sweden
Other
Eligibility
23 Weeks to 31 Weeks
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
2
States / cities
San Francisco, California • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 5, 2026, 5:50 AM EDT
Completed No phase listed Observational Results available

Treatment With Adenosine Diphosphate (ADP) Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome

NCT01088503
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
ADP receptor inhibitors
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
12,227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
185
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 182 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 5, 2026, 5:50 AM EDT
Completed No phase listed Observational

Positional Cloning of the Gene(s) Responsible for Alagille Syndrome

NCT00001642
View directory record Official record
Conditions
Alagille Syndrome
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Phase 2 Interventional

Sodium-Glucose Cotransporter-2 Inhibitor for Acute Cardiorenal Syndrome: A Feasibility Study

NCT06111768
View directory record Official record
Conditions
Cardiorenal Syndrome
Interventions
Dapagliflozin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Phase 4 Interventional Results available

Tailored Antiplatelet Therapy Following PCI

NCT01742117
View directory record Official record
Conditions
Coronary Artery Disease, Acute Coronary Syndrome, Stenosis
Interventions
Clopidogrel, Ticagrelor
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
5,276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
26
States / cities
Scottsdale, Arizona • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Oct 5, 2026, 5:50 AM EDT
Recruiting No phase listed Observational

The Co-Op @ HeartWorks

NCT06469918
View directory record Official record
Conditions
Congenital Heart Disease
Interventions
Not listed
Lead sponsor
HeartWorks, Inc.
Other
Eligibility
0 Years and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2050
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 5, 2026, 5:50 AM EDT
Completed Not applicable Interventional Results available

Sleep Apnea Intervention for Cardiovascular Disease Reduction

NCT01261390
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Conservative Medical Therapy (CMT), Sham PAP (Sham), Active PAP with RT Support (Active-Beh), Active PAP with Behavioral Modification (Active+Beh)
Behavioral · Device
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
45 Years to 75 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 5, 2026, 5:50 AM EDT
Not listed Phase 2Phase 3 Interventional

Half-dose Ticagrelor Overcomes High-dose Clopidogrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity

NCT03062462
View directory record Official record
Conditions
Coronary Artery Disease, Clopidogrel, Poor Metabolism of
Interventions
Clopidogrel, ticagrelor
Drug
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Other
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Havertown, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Oct 5, 2026, 5:50 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Heart Disease Risk Factors in Major Depression

NCT00001969
View directory record Official record
Conditions
Adrenal Gland Hyperfunction, Cardiovascular Disease, Involutional Depression
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
21 Years to 55 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 5, 2026, 5:50 AM EDT